Eikonoklastes Therapeutics
0 followers
‌
Eikonoklastes is advancing a new generation of tissue factor (TF) immunotherapies – therapeutics designed to target the cell surface receptor now known to be prevalent on key components of the tumor microenvironment.
Industries
Headquarters
Employees
Links
Org chart
Bruce Halpryn
Co-Founder & CEO
Bruce Halpryn
Collapse
Samuel Lee
Co-Founder & Chief Business Officer
Vishal Agrawal
VP, CMC
Samuel Lee, MD, MBA
Co-Founder, President, and Chief Business Officer
